Objective:

To identify novel protein biomarkers that may help monitor the progression of Hutchinson-Gilford progeria syndrome (HGPS) and the effect of therapeutics.

Approach:

• Biomarker Identification: The study involved assessing various hematologic tests based on clinical disease characteristics and organ function, utilizing advanced technology to analyze multiple proteins from small blood samples.
• Multiplex Assay: A multiplex study was chosen to evaluate a large number of proteins using limited plasma volume, ensuring sensitivity and specificity.

Key Findings:

• A significant number of proteins were found to differ between children with HGPS and non-HGPS controls.
• The rarity of HGPS (one in 20 million) necessitates reliable testing platforms due to the limited blood sample volume from affected children.

Interpretation:

Limitations:

• The small blood volume available from children with HGPS limits the number of tests that can be performed.
• Funding and resources for research into rare diseases remain a challenge.

Conclusion:

Sources:

• Progeria Research Foundation